Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer ... contribute to a stable global vaccine supply, and achieve ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

In 2020, Pfizer claimed ... transfers through local partnerships are also being pursued in parallel. Looking ahead, SK bioscience aims to expand its presence in the global pneumococcal vaccine ...

including obesity by advancing internal programs such as our GIPR antagonist and pursuing external opportunities that could include partnerships or acquisitions. While Chris Boshoff, Pfizer's ...

While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

The Dementia Discovery Fund ("DDF"), managed by SV Health Investors, today announced the final closing of its second fund, DDF-2, with $269m in commitments. DDF is the world's largest family of ...